PRIO – a prospective integrative oncology registry: trial protocol
The PRIO registry builds a solid data base to evaluate the use of integrative oncology measures in cancer patients. It includes patient reported outcome measures to investigate quality of life and satisfaction with health services in this population. The registry aims to enhance transparency in IO use and wants to inform future research in IO. The trial has been registered in the German Clinical Trials Register (DRKS) under the ID DRKS00033250 and in the studyBox of the German Cancer Association under the ID ST-U173 on 18th December 2023. The trial was approved by the ethics committee of the University Medical Center Ulm under the number 375/23 on 7th December 2023.
Authors
- Paul G. Werthmann (ORCID: https://orcid.org/0000-0002-1808-7787)
- Klaus Kramer (ORCID: https://orcid.org/0009-0004-0257-6318)
- Ann‐Kathrin Lederer (ORCID: https://orcid.org/0000-0001-7984-9530)
- Hannah Maja Figura
Institutions
- Witten/Herdecke University (DE)
- University of Freiburg (DE)
- Johannes Gutenberg University Mainz (DE)
- University Medical Center Freiburg (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.3389/fonc.2024.1455281
- Primary Topic
- Cancer survivorship and care
- Type
- article
- Field-Weighted Citation Impact
- 0.00